JP Patent

JP7234418B2 — Ｂｒａｆｖ６００ｅ大腸癌の治療に使用するためのｅｒｋ１／２阻害剤と、ｂｒａｆ阻害剤およびｅｇｆｒ阻害剤との三重組み合わせ

Assigned to イーライ リリー アンド カンパニー · Expires 2023-03-07 · 3y expired

What this patent protects

Patent listed against Mektovi.

Drugs covered by this patent

Patent Metadata

Patent number
JP7234418B2
Jurisdiction
JP
Classification
—
Expires
2023-03-07
Drug substance claim
No
Drug product claim
No
Assignee
イーライ リリー アンド カンパニー
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.